Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
Approval based on pivotal CABINET Phase III trial which demonstrated a 77% and 62% reduction in the risk of disease progression or death versus placebo in advanced pancreatic and extra-pancreatic neuroendocrine tumors, respectively3,4
PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
14 hours ago
- Cision Canada
ACCESSA LAUNCHES OSTEOACCES, AN INNOVATIVE THERAPEUTIC ADHERENCE PROGRAM FOR PATIENTS WITH OSTEOPOROSIS Français
MONTREAL, July 29, 2025 /CNW/ - Accessa is proud to announce the launch of OSTEOACCES, the very first therapeutic adherence program under its new ADHAESIO TM line, designed to promote medication adherence through a patient-centered care approach. Osteoacces marks a significant step forward in supporting patients with osteoporosis who are being treated with denosumab. The program provides pharmacies with tools and additional resources to better support patients throughout their treatment. This innovative initiative aims to improve therapeutic adherence, a key factor in treatment success. By placing patients at the heart of our approach, we believe Osteoacces can enhance their experience at every stage of their care journey. Accessa leverages its unique technology platform, Curo TM, to guide and support community pharmacies throughout the treatment process. This results in optimal medication use and, consequently, better health outcomes. "The WHO reports that 50% of patients treated for a chronic disease do not adhere to their prescribed medication 1. In the case of patients with osteoporosis, adherence to treatment is a determining factor in therapeutic success, as non-adherence has been associated with an increased risk of fractures 2. With Osteoacces, we're offering a concrete, inclusive, and accessible solution for patients undergoing treatment for osteoporosis," says Jean Bourcier, President of Accessa. Sandoz Canada is the first manufacturer to join the program with Jubbonti ®, the first and only biosimilar of denosumab (reference product Prolia ®) approved by Health Canada. "Sandoz is proud to be a business partner to pharmacies across Quebec, supporting pharmacists in the care and management of their patients." Osteoacces is open to all manufacturers commercializing a biosimilar for the treatment of osteoporosis who wish to partner with Accessa to promote patient adherence to treatment. A new range of programs focused on patients' medical conditions This launch is part of a broader vision led by the Adhaesio ™ program line, which will include several therapeutic adherence programs, each dedicated to a specific molecule or health condition. Each Adhaesio™ program will promote medication adherence by supporting pharmacist-led care, regardless of the prescribed brand. This approach enables both patients and healthcare professionals to focus on achieving successful treatment outcomes. About Accessa Accessa is the manager of a new generation of patient support programs (PSPs), fully owned by Quebec's community pharmacists through the Association québécoise des pharmaciens propriétaires (AQPP). Our mission is to provide our partners with innovative, compliant, and scalable solutions that enable patients to access comprehensive management of their medication therapy including complex treatments through the pharmacist of their choice.
Cision Canada
14 hours ago
- Cision Canada
DQ's Miracle Treat Day Returns August 14 with Canadian Hockey Icon Brad Marchand to Support Children's Hospitals Across Canada
TORONTO, July 29, 2025 /CNW/ - Thursday, August 14 marks DQ® Canada's 23 rd annual Miracle Treat Day. This year, Canadian hockey icon Brad Marchand joins the celebration to support local children's hospitals through the Children's Miracle Network®. For every Blizzard® Treat sold at participating locations across Canada, net proceeds will support 12 children's hospital foundations nationwide. All funds raised stay in the communities where they're collected. DQ Canada is proud to team up with celebrated hockey champion and known Blizzard Treat lover, Brad Marchand. A proud father from Halifax, Marchand is helping raise awareness for the cause. "As a dad, supporting children's health, especially through Canadian children's hospitals, is something I care deeply about," said Marchand. "Buying a Blizzard Treat may seem like a small thing but on Miracle Treat Day it's part of something so much bigger." Since 1984, in Canada more than $55 million has been raised in support of children's health through Miracle Treat Day. "This is one of the most inspiring days of the year for all of us at DQ," said Candida Ness, Vice President of Marketing at DQ Canada. "Our franchisees and fans always show up in such a meaningful way and their continued support speaks to the incredible impact this campaign has had. We're proud to keep that momentum going." Funds raised on Miracle Treat Day support each hospital's most urgent priorities, ensuring kids receive the care and support they need most. In 2024 alone, Canadian children's hospitals recorded more than three million visits. On Miracle Treat Day, DQ franchisees, staff and volunteers come together in communities across the country to raise money for local hospital foundations and help ensure kids can access the care they need, close to home. "DQ Canada has been a committed partner in children's health for more than four decades, and Miracle Treat Day is a powerful example of what happens when communities rally together," said Adam Starkman, President and CEO of Canada's Children's Hospital Foundation. "Every Blizzard Treat sold helps fuel groundbreaking research and discovery, life-changing innovations and healing environments that make the hospital experience less overwhelming for families, ultimately, helping kids get back to being kids." For more information about Miracle Treat Day, visit Fans are encouraged to share their support by taking a photo with their Blizzard Treat and sharing it with the hashtag #MiracleTreatDay on the following social platforms, tagging the handles below: Facebook - @DQCanada @CMNcanada Instagram - @dqcanada @cmncanada About IDQ International Dairy Queen Inc. (IDQ), based in Minneapolis, Minnesota, is the parent company of American Dairy Queen Corporation (ADQ) and Dairy Queen Canada, Inc. Through its subsidiaries, IDQ develops, licenses and services a system of more than 7,000 restaurants in the United States, Canada and more than 20 other countries. IDQ is a subsidiary of Berkshire Hathaway, Inc. (Berkshire), which is led by Warren Buffet, the legendary investor and CEO of Berkshire. For more information, visit About Children's Miracle Network Children's Miracle Network® raises funds and awareness for 170 member hospitals, 13 of which are in Canada. Donations stay local to fund critical treatments and healthcare services, purchase pediatric medical equipment, and support research. Its various fundraising partners and programs support its mission to save and improve the lives of as many children as possible. Visit the Children's Miracle Network website to learn more about its cause. In Canada, Children's Miracle Network is managed and operated by Canada's Children's Hospital Foundations®.
Toronto Star
2 days ago
- Toronto Star
Impulse Dynamics® Completes Enrollment of Pivotal Trial for CCM-D® HF System and Earns Category 1 CPT Codes for CCM® Therapy
MARLTON, N.J., July 28, 2025 (GLOBE NEWSWIRE) — Impulse Dynamics®, a global medical device company committed to improving the lives of people with heart failure (HF), announced two major accomplishments, marking an inflection point in the advancement and accessibility of CCM® Therapy. The company successfully completed enrollment in the INTEGRA-D™ Pivotal Trial. This marks a significant milestone in the journey to introduce the CCM-D® HF System, the world's first device combining Impulse Dynamics®' proprietary CCM® therapy for the treatment of HF symptoms with lifesaving, implantable cardioverter defibrillator (ICD) therapy. The trial's initial results, including 100 percent defibrillation success in the efficacy cohort, were presented as a late-breaking clinical trial at Heart Rhythm 2025 and support a forthcoming PMA submission to the FDA. This milestone advances the potential approval of a first-of-its-kind dual therapy that is designed to address both sudden cardiac death and chronic HF symptoms. The American Medical Association (AMA) granted Category I Current Procedural Terminology (CPT) codes for CCM® Therapy. This designation confirms the procedure is both widely performed and supported by strong clinical evidence. Sponsored by the American College of Cardiology (ACC) and Heart Rhythm Society (HRS), this coding advancement represents a major breakthrough in reimbursement access, establishing CCM® as a mainstream therapeutic option. It streamlines insurance billing and lays the foundation for widespread adoption and coverage in the U.S. market.
